Shang Hai Zheng Quan Bao·2026-01-12 18:12Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. has successfully applied to revoke the delisting risk warning after the court terminated its restructuring process, allowing the company to continue trading under other risk warnings [2][3]. Group 1: Stock Trading and Risk Warnings - The delisting risk warning was lifted on January 12, 2026, and the stock will be traded under the name "ST Ningke" starting January 14, 2026, after a one-day suspension on January 13, 2026 [2][4]. - The stock price will still be subject to a daily fluctuation limit of 5% as it remains on the risk warning board [2]. Group 2: Financial Performance and Other Risks - The company has faced continuous losses, with a net profit of -53,890.69 million yuan for the year 2024, and a net profit of -40,467.35 million yuan after deducting non-recurring gains and losses [5]. - The company has been under other risk warnings since April 8, 2024, due to its subsidiary entering a production halt and ongoing uncertainties regarding sustainable operational capabilities [5][6]. - As of the third quarter of 2025, the company reported revenue of 32,735.24 million yuan and a net profit attributable to shareholders of -25,097.92 million yuan, with net assets of -17,918.57 million yuan [7].